Bridging the innate to adaptive immune response
Highlight (ex Bioncotech) is a clinical-stage, immune-oncology company focused on developing a cutting-edge RNA-based therapies against validated and novel targets in cancer and immune cells.
CEO Marisol Quintero
Advent Contact Shahzad Malik
Private Companies
Highlight Therapeutics announces follow-up results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at AACR
Press Release. BO-112 demonstrates potential as new and highly effective second line therapy for melanoma BO-112 demonstrates potential as best-in-class therapy to overcome anti-PD1 resistance in melanoma patients whose…
Read More
Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
Press Release. Final results of SPOTLIGHT203 phase 2 study demonstrate new approach to second line treatment for melanomaMadrid, Spain, 15 March, 2022 – Highlight Therapeutics, (“Highlight”), a clinical-stage biopharmaceutical…
Read More
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO-112 + STING agonist published in Journal for ImmunoTherapy of Cancer
Press Release. Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 results of…
Read More
Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC
Press Release. Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC Breakthrough cancer treatment shows best-in-class…
Read More
